Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide

SIMPLE SUMMARY: Glioblastoma (GBM) resistance to standard treatment is driven by stem-like cell behavior and epithelial-like-mesenchymal transition. The main purpose of this paper was to functionally validate a novel discovered pharmacological strategy to treat GBM, the dual mTOR pathway inhibitor R...

Descripción completa

Detalles Bibliográficos
Autores principales: Vargas-Toscano, Andres, Nickel, Ann-Christin, Li, Guanzhang, Kamp, Marcel Alexander, Muhammad, Sajjad, Leprivier, Gabriel, Fritsche, Ellen, Barker, Roger A., Sabel, Michael, Steiger, Hans-Jakob, Zhang, Wei, Hänggi, Daniel, Kahlert, Ulf Dietrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766508/
https://www.ncbi.nlm.nih.gov/pubmed/33371210
http://dx.doi.org/10.3390/cancers12123859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766508/
https://www.ncbi.nlm.nih.gov/pubmed/33371210
http://dx.doi.org/10.3390/cancers12123859

Ejemplares similares